AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD
20 juin 2024 08h00 HE
|
AUROBAC THERAPEUTICS
The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy. Lyon (France), June 20, 2024 ...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
20 juin 2024 07h00 HE
|
atai Life Sciences
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of...
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
20 juin 2024 06h30 HE
|
Ocugen
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Forbion announces first close of its new BioEconomy Fund I: backing biotech-enabled companies aiming to impact the future of our planet
20 juin 2024 01h25 HE
|
Forbion
Forbion announces the first close of its latest fund, Forbion BioEconomy Fund I (“Forbion BioEconomy"), at €75 million.
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
18 juin 2024 11h35 HE
|
XBiotech Inc.
AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced...
Biotechnology for the Non-Biotechnologist Training Course: Latest Advances in Regulation, Including Biosimilars and Advanced Therapies (ONLINE EVENT: June 24-28, 2024/On-Demand)
18 juin 2024 11h27 HE
|
Research and Markets
Dublin, June 18, 2024 (GLOBE NEWSWIRE) -- The "Biotechnology for the Non-Biotechnologist Training Course" conference has been added to ResearchAndMarkets.com's offering. This intensive three-day...
Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET
18 juin 2024 08h16 HE
|
Pressure BioSciences, Inc.
NOTE CHANGE IN DATE OF PRESSURE BIOSCIENCES UPDATE CALL TO THURSDAY JUNE 20th
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
18 juin 2024 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,...
Plant Extracts Global Strategic Business Report 2023-2024 & 2030
17 juin 2024 10h20 HE
|
Research and Markets
Dublin, June 17, 2024 (GLOBE NEWSWIRE) -- The "Plant Extracts - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Plant Extracts is...
Assembly Biosciences Announces $12.6 Million in Equity Financings
17 juin 2024 08h00 HE
|
Assembly Biosciences, Inc.
— Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runway into Q1 2026 — — Anticipated near term interim data read outs include...